Linked Data API

Show Search Form

Search Results

1692464
registered interest false more like this
date less than 2024-02-28more like thismore than 2024-02-28
answering body
Cabinet Office more like this
answering dept id 53 more like this
answering dept short name Cabinet Office more like this
answering dept sort name Cabinet Office more like this
hansard heading Blood: Contamination more like this
house id 1 more like this
legislature
25259
pref label House of Commons remove filter
question text To ask the Minister for the Cabinet Office, if he will make an estimate of how many people would be eligible for compensation under the terms of the recommendations of the second interim report of Infected Blood Inquiry, published on 5 April 2023, in Glenrothes constituency. more like this
tabling member constituency Glenrothes more like this
tabling member printed
Peter Grant more like this
uin 16156 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-03-04more like thismore than 2024-03-04
answer text <p>The Statistical Expert Group, established by the Infected Blood Inquiry, has provided valuable insight into the numbers of infections from blood and blood products in the UK between 1970 and 1991 and subsequent survival rates. Since October 2022, the Government has paid over £400 million in interim compensation payments to those infected or bereaved partners registered with the UK Infected Blood Support Schemes, totalling over 4,000 individuals. However, the requested information is not available by Parliamentary constituency. There is also considerable uncertainty over the number of people, especially those affected, who might be eligible under Sir Brian Langstaff’s recommendations. Therefore I am not able to provide a substantive response to the Honourable Member’s questions on his constituency.</p><p> </p> more like this
answering member constituency Salisbury more like this
answering member printed John Glen more like this
grouped question UIN 16157 more like this
question first answered
less than 2024-03-04T16:33:31.513Zmore like thismore than 2024-03-04T16:33:31.513Z
answering member
4051
label Biography information for John Glen more like this
tabling member
4466
label Biography information for Peter Grant remove filter
1692465
registered interest false more like this
date less than 2024-02-28more like thismore than 2024-02-28
answering body
Cabinet Office more like this
answering dept id 53 more like this
answering dept short name Cabinet Office more like this
answering dept sort name Cabinet Office more like this
hansard heading Blood: Contamination more like this
house id 1 more like this
legislature
25259
pref label House of Commons remove filter
question text To ask the Minister for the Cabinet Office, how many people have received interim compensation payments as a result of (a) their infection and (b) their family member’s infection resulting from contaminated blood or blood products in Glenrothes constituency. more like this
tabling member constituency Glenrothes more like this
tabling member printed
Peter Grant more like this
uin 16157 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-03-04more like thismore than 2024-03-04
answer text <p>The Statistical Expert Group, established by the Infected Blood Inquiry, has provided valuable insight into the numbers of infections from blood and blood products in the UK between 1970 and 1991 and subsequent survival rates. Since October 2022, the Government has paid over £400 million in interim compensation payments to those infected or bereaved partners registered with the UK Infected Blood Support Schemes, totalling over 4,000 individuals. However, the requested information is not available by Parliamentary constituency. There is also considerable uncertainty over the number of people, especially those affected, who might be eligible under Sir Brian Langstaff’s recommendations. Therefore I am not able to provide a substantive response to the Honourable Member’s questions on his constituency.</p><p> </p> more like this
answering member constituency Salisbury more like this
answering member printed John Glen more like this
grouped question UIN 16156 more like this
question first answered
less than 2024-03-04T16:33:31.557Zmore like thismore than 2024-03-04T16:33:31.557Z
answering member
4051
label Biography information for John Glen more like this
tabling member
4466
label Biography information for Peter Grant remove filter
1689378
registered interest false more like this
date less than 2024-02-16more like thisremove minimum value filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Oxcarbazepine more like this
house id 1 more like this
legislature
25259
pref label House of Commons remove filter
question text To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that there is an adequate supply of oxcarbazepine for patients with epilepsy. more like this
tabling member constituency Glenrothes more like this
tabling member printed
Peter Grant more like this
uin 14277 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-02-21more like thismore than 2024-02-21
answer text <p>The Department was informed of supply issues with oxcarbazepine 150 milligram and 300 milligram tablets by one supplier, which are out of stock until the end of March and the end of February 2024, respectively. Alternative oxcarbazepine tablets remain available. The Department has worked extensively with alternative suppliers and clinical colleagues and has since issued communications to the National Health Service which includes detailed management advice.</p><p>While we cannot always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise and help mitigate risks to patients. There is a team within the Department that deals specifically with medicine supply problems, and it works closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England, the devolved administrations, and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when shortages do arise.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-02-21T09:42:48.583Zmore like thismore than 2024-02-21T09:42:48.583Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4466
label Biography information for Peter Grant remove filter